Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Telmisartan
Amlodipine
Chlorthalidone
Sponsored by

About this trial
This is an interventional basic science trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Participant who has a body weight that is ≥55kg(male) or ≥50kg(female) with ideal body weight of 80-120% (ideal body weight)
- Who has not suffered from clinically significant disease
- Provision of signed written informed consent
Exclusion Criteria:
- History of and clinically significant disease psychiatric, or malignancy.
- A history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs.
- Administration of other investigational products within 3 months prior to the first dosing.
- Administration of herbal medicine within 2 weeks or administration of ethical drugs within 2 weeks or administration of over-the-counter (OTC) drugs within 1 week prior to the first dosing of the investigational product (if the investigator (study doctor) determines that the person meets other criteria appropriately, the relevant person may participate in the study).
- Volunteers considered not eligible for the clinical trial by the investigator (study doctor) due to reasons including laboratory test results, ECGs, or vital signs.
Sites / Locations
- The Catholic University of Korea Seoul St.Mary's Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Part B
Part A
Arm Description
Arm to evaluate influence of Chlorthalidone on pharmacokinetics of amlodipine and telmisartan.
Arm to evaluate influence of amlodipine and telmisartan on pharmacokinetics of Chlorthalidone.
Outcomes
Primary Outcome Measures
AUCt ss, Cmax ss of telmisartan/amlodipine/chlorthalidone
Secondary Outcome Measures
Cmin ss, tmax ss, t1/2 of telmisartan/amlodipine/chlorthalidone
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02152969
Brief Title
Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)
Official Title
An Open-label, Multiple-dose, Two-arm Clinical Study to Evaluate the Drug-drug Interaction and Safety of Telmisartan, Amlodipine and/or Chlorthalidone in Healthy Adult Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
November 2014
Overall Recruitment Status
Completed
Study Start Date
May 2014 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
November 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yuhan Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To evaluate Drug-drug interaction
Detailed Description
The purpose of this study is to evaluate the Drug-Drug(telmisartan, amlodipine and/ or chlorthalidone) interaction and safety in healthy adult volunteers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
66 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Part B
Arm Type
Other
Arm Description
Arm to evaluate influence of Chlorthalidone on pharmacokinetics of amlodipine and telmisartan.
Arm Title
Part A
Arm Type
Other
Arm Description
Arm to evaluate influence of amlodipine and telmisartan on pharmacokinetics of Chlorthalidone.
Intervention Type
Drug
Intervention Name(s)
Telmisartan
Intervention Type
Drug
Intervention Name(s)
Amlodipine
Intervention Type
Drug
Intervention Name(s)
Chlorthalidone
Primary Outcome Measure Information:
Title
AUCt ss, Cmax ss of telmisartan/amlodipine/chlorthalidone
Time Frame
Totally 28points for 24 hours
Secondary Outcome Measure Information:
Title
Cmin ss, tmax ss, t1/2 of telmisartan/amlodipine/chlorthalidone
Time Frame
Totally 28points for 24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Participant who has a body weight that is ≥55kg(male) or ≥50kg(female) with ideal body weight of 80-120% (ideal body weight)
Who has not suffered from clinically significant disease
Provision of signed written informed consent
Exclusion Criteria:
History of and clinically significant disease psychiatric, or malignancy.
A history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs.
Administration of other investigational products within 3 months prior to the first dosing.
Administration of herbal medicine within 2 weeks or administration of ethical drugs within 2 weeks or administration of over-the-counter (OTC) drugs within 1 week prior to the first dosing of the investigational product (if the investigator (study doctor) determines that the person meets other criteria appropriately, the relevant person may participate in the study).
Volunteers considered not eligible for the clinical trial by the investigator (study doctor) due to reasons including laboratory test results, ECGs, or vital signs.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dong Seok Yim
Organizational Affiliation
The Catholic University of Korea
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Catholic University of Korea Seoul St.Mary's Hospital
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)
We'll reach out to this number within 24 hrs